Trevi Therapeutics Q3 2026 Results: Net Loss of $21.5M, Loss Widens
Trevi Therapeutics reported a net loss of $52.4 million for the nine months ended September 30, 2026, compared to $34.4 million in the prior year, primarily driven by increased R&D expenses for its Haduvio clinical trials. The company significantly strengthened its balance sheet through a common stock offering, ending the period with $299.4 million in cash, cash equivalents, and marketable securities.
- Key figure
- Net loss $21.5M